Inventor · disambiguated record
Simone Greven
Also filed as: GREVEN SIMONE
20 granted patents·24 pending applications·116 citations·filing 2007–2025
94Inventor score
Top patents by PatentIndex Score
44 records- 0195US11478554B2Antibody drug conjugates (ADCS) having enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Oct 25, 2022·5 cites·20 claims
- 0294US10973923B2Site specific homogeneous with KSP inhibitorsBayer Pharma AG·Filed 2016·Granted Apr 13, 2021·8 cites·37 claims
- 0394US10022453B2Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)Bayer Pharma AG·Filed 2014·Granted Jul 17, 2018·16 cites·39 claims
- 0492US11643469B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2022·Granted May 9, 2023·1 cites·15 claims
- 0592US11123439B2Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groupsBayer Pharma AG·Filed 2016·Granted Sep 21, 2021·8 cites·51 claims
- 0692US10744205B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodiesBayer Pharma AG·Filed 2016·Granted Aug 18, 2020·9 cites·28 claims
- 0792US8992932B2Binder-drug conjugates (ADCs) and use thereofSEATTLE GENETICS INC·Filed 2012·Granted Mar 31, 2015·26 cites·12 claims
- 0891US11660351B2Antibody drug conjugates (ADCs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted May 30, 2023·5 cites·50 claims
- 0990US11001636B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2017·Granted May 11, 2021·5 cites·15 claims
- 1089US11071788B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodiesBayer Pharma AG·Filed 2016·Granted Jul 27, 2021·6 cites·32 claims
- 1189US10485880B2Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodiesBayer Pharma AG·Filed 2015·Granted Nov 26, 2019·11 cites·29 claims
- 1287US11685714B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted Jun 27, 2023·3 cites·30 claims
- 1381US2023399411A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1480US9777063B2Neutralizing prolactin receptor antibody Mat3 and its therapeutic useBAYER IP GMBH·Filed 2016·Granted Oct 3, 2017·3 cites·4 claims
- 1580US2025099600A1Active Metabolites of Kinesin Spindle Protein Inhibitor ConjugatesBayer Pharma AG·Filed 2024·Application pending·0 cites
- 1676US9649374B2Neutralizing prolactin receptor antibodies and their therapeutic useOTTO CHRISTIANE·Filed 2010·Granted May 16, 2017·5 cites·5 claims
- 1775US2023338559A1Antibody drug conjugates (adcs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1873US12059472B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBAYER AG·Filed 2017·Granted Aug 13, 2024·1 cites·15 claims
- 1971US2021230284A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2021·Application pending·0 cites
- 2070US2024043379A1Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 2168US12144865B2Antibody drug conjugates with enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Nov 19, 2024·0 cites·33 claims
- 2268US9241989B2Neutralizing prolactin receptor antibodies and their therapeutic useOTTO CHRISTIANE·Filed 2010·Granted Jan 26, 2016·2 cites·16 claims
- 2366US9353186B2Neutralizing prolactin receptor antibody Mat3 and its therapeutic useFREIBERG CHRISTOPH·Filed 2012·Granted May 31, 2016·2 cites·14 claims
- 2464US11806404B2Site specific homogeneous with KSP inhibitorsBayer Pharma AG·Filed 2021·Granted Nov 7, 2023·0 cites·18 claims
- 2561US2015030618A1Novel binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2014·Application pending·0 cites
- 2661US2025361282A1Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2025·Application pending·0 cites
- 2759US12331094B2Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2019·Granted Jun 17, 2025·0 cites·18 claims
- 2857US2014127240A1Novel Binder-Drug Conjugates (ADCs) and Use of SameLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 2957US2013122024A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 3056US2013066055A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 3156US2016193359A1New binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2016·Application pending·0 cites
- 3254US2015246136A1NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAMESEATTLE GENETICS INC·Filed 2015·Application pending·0 cites
- 3351US2017158775A1Anti-c4.4a antibodies and uses thereofBAYER IP GMBH·Filed 2017·Application pending·0 cites
- 3450US2020360531A1Antibody drug conjugates (adcs) with nampt inhibitorsBAYER AG·Filed 2019·Application pending·0 cites
- 3549US2021275686A1Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profileBAYER AG·Filed 2019·Application pending·0 cites
- 3647US2014322220A1Anti-FGFR2 Antibodies and Uses ThereofBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 3747US2015023989A1New antibody drug conjugates (adcs) and the use thereofSEATTLE GENETICS INC·Filed 2012·Application pending·0 cites
- 3843US2009170766A1Chimeric Kunitz Domains and their UseBAYER HEALTHCARE AG·Filed 2007·Application pending·0 cites
- 3943US2016237160A1Anti-tweakr antibodies and uses thereofBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4043US2016009776A1Pdgfrbeta-fc fusion proteins and uses thereofBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4142US2014050743A1Binding proteins to inhibitors of coagulation factorsDITTMER FRANK·Filed 2012·Application pending·0 cites
- 4241US2012321619A1Anti-c4.4a antibodies and uses thereofLINDEN LARS·Filed 2010·Application pending·0 cites
- 4339US2018318438A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 4436US2018185510A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Simone Greven files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →